SCHEMBL4397339

SCHEMBL4397339

COc1ccc(Cn2c(-c3cccc(Br)c3)c(-c3cccc(Br)c3)n(Cc3ccc(OC)cc3)c2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.49
MAPK8 P45983 1/20 0.48
CFTR P13569 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 6/20 0.46
THRB P10828 1/20 0.46
LMNA P02545 4/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 3/20 0.45
HTT P42858 2/20 0.45
CNR2 P34972 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13307022 0.82 CFTR (0.46) P2RX4MAPK8CFTRSMN1; SMN2MAPT
SCHEMBL4397609 0.80 HDAC1 (0.46) P2RX4SMN1; SMN2POLBGAAMAPK1
SCHEMBL30996182 0.71 ABL1 (0.63) SMN1; SMN2MAPK1MAPTLMNAALDH1A1
SCHEMBL1181012 0.71 ABL1 (0.63) SMN1; SMN2MAPK1MAPTLMNAALDH1A1
SCHEMBL5875455 0.71 CASP3 (0.58) P2RX4SMN1; SMN2POLBGAAMAPK1
SCHEMBL5891433 0.71 CASP3 (0.58) P2RX4SMN1; SMN2POLBGAAMAPK1
SCHEMBL4397334 0.70 MEN1 (0.47) MAPTTHRBLMNAALDH1A1MEN1
SCHEMBL13307299 0.69 MAPT (0.41) P2RX4SMN1; SMN2GAAMAPTTHRB
SCHEMBL24307080 0.69 PDE5A (0.65) P2RX4MAPK8SMN1; SMN2POLBGAA
SCHEMBL31042159 0.69 PDE5A (0.65) P2RX4MAPK8SMN1; SMN2POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 P2RX4 1085/4885MAPK8 3629/4885CFTR 392/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A P2RX4 456/4885MAPK8 3824/4885CFTR 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.